Wednesday, March 28, 2012

Clot Wars contd. Xarelto single pill beats enoxaparin, VKA combo

Bayer HealthCare announced today that the oral anticoagulant Xarelto® (rivaroxaban), used as a single drug intervention, was as effective and safe as the current dual drug approach of subcutaneous enoxaparin followed by Vitamin K antagonist (VKA), in treating patients with acute symptomatic pulmonary embolism (PE) and preventing them from developing a secondary venous thromboembolism (VTE).

No comments: